Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone